IL6R and juvenile idiopathic arthritis: It was reported that tocilizumab, a humanized anti-IL-6R monoclonal antibody, improved the signs and symptoms of rheumatoid arthritis [105–110], juvenile idiopathic arthritis [111–113], and Castleman disease [114–116].